Ottawa, Ontario (PRWEB) October 09, 2013
Spartan Bioscience today announced Appleton Medical as the distributor for its rapid CYP2C19 testing system in the central United States.
The Spartan RX CYP2C19 System provides CYP2C19 test results in less than 60 minutes from a non-invasive cheek swab. It helps doctors determine therapeutic strategies for drugs metabolized by the CYP450 2C19 genetic pathway, which include anti-platelet therapies, beta blockers and proton pump inhibitors. The sample-to-result system is FDA 510(k) cleared for clinical use in the United States.
“Appleton Medical has over 30 years of experience in bringing innovative healthcare products to physicians and hospitals,” said Paul Lem, M.D., CEO of Spartan Bioscience. “There is a tremendous market opportunity and we are seizing it together.”
"The Spartan RX CYP2C19 System helps doctors treat patients faster with the most effective drugs,” said Terry Dougherty, President and CEO of Appleton Medical. “We are excited to make personalized medicine a reality.”
The CYP2C19 enzyme metabolizes approximately 15 percent of all prescribed drugs(1), including important drug classes such as anti-platelet therapies, beta blockers, anti-depressants, proton pump inhibitors, and anti-epileptics. About 30% of Caucasians, 40% of Africans, and more than 50% of Asians and Indians carry CYP2C19 gene variants that reduce response to drugs metabolized by CYP2C19.(2,3,4,5)
About Spartan Bioscience
Spartan Bioscience is the leader in on-demand DNA testing. Spartan is bringing complete sample-to-result DNA testing systems to medicine. Spartan’s technology fully integrates DNA collection, extraction and analysis, with an intuitive interface that is easy to operate. For the first time, healthcare providers and their patients can get DNA results on demand. For more information, please visit our website at: http://www.spartanbio.com.
The Spartan logo is a registered trademark of Spartan Bioscience Inc.
1. dbSNP Short Genetic Variations. Reference SNP (refSNP) Cluster Report: rs12248560
2. Damani SB, Topol EJ. (2010). J Am Coll Cardiol. 56:109–11.
3. Chen M et al. (2011). Atherosclerosis. 220(1):168–71.
4. Oh IY et al. (2012). Heart. 98(2):139–44.
5. Jose R et al. (2004). Fundamental & Clinical Pharmacology. 19(1): 101–105.
6. Roberts JD et al. (2012). Lancet. 379:1705–11.